Monday Apr 14
Orion receives first marketing authorisations for Bufomix Easyhaler product
ORION CORPORATION STOCK EXCHANGE RELEASE 14 APRIL 2014 at 9:30 PM EEST Orion receives first marketing authorisations for Bufomix Easyhaler product Orion Corporation has received Irish and Hungarian marketing authorisation for Bufomix Easyhaler , an inhaled budesonide-formoterol combination product indicated for asthma and chronic obstructive ... (more)
Investigation Report on China Budesonide Market
Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere becomes more and more seriously contaminated, incidence of these diseases increases year by year.